Новости рынков | Новости фондового рынка США – NYSE, NASDAQ на 14.07.2017

Вниз

Реакция на earnings/guidance:

• CYBR -19.4%, (lowers Q2 sales, profit guidance primarily because deals in EMEA did not close in time), WPRT -16.5%, ATEN -16.3%, (sees Q2 results below consensus), ACIA -7.6%, JPM -1.2%, WFC -1.1%

Select CYBR peers showing weakness:

• FEYE -2.9%, PANW -2.1%, FTNT -2%, HACK -1.4%, SYMC -1.2%, IMPV -0.7%, PFPT -0.5%

Другие новости

• CHKE -8.3% (obtains further extension of forbearance through July 28)
• SHLO -5% (prices 5 mln shares of common stock at $8.25 per share)
• WY -4.5% (announced effective immediately the ban of all campfires on its lands in Flathead, Lake, Lincoln, Missoula, Sanders and Ravalli counties in Western Montana due to high fire danger)
• INSY -2.3% (WSJ reporting Anthem has launched civil suit against Insys) 
• ATHN -1.3% (CFO Karl Stubelis to step down; FY17 guidance reaffirmed)

Комментарии аналитиков:

• HIMX -4.9% (downgraded to Underperform at Oppenheimer; tgt $4)
• FFIV -4% (downgraded to Neutral from Overweight at Piper Jaffray)
• SNAP -2% (downgraded to Market Perform at Cowen)
• AVT -1.1% (downgraded to Underperform at BofA/Merrill)

Вверх
Реакция на earnings/guidance:

• MDXG +7.9%, PNC +0.5%

Другие новости

• CLIR +37.5% (receives order from supermajor oil company to qualify Duplex technology)
• CGI +14.9% (appoints Paul Svindland as CEO effective on or about July 24; Michael Miller, current lead independent director, to become Chairman)
• CTIC +11.2% (announces that European Medicines Agency has validated the Marketing Authorization Application for pacritinib for the treatment of patients with myelofibrosis who have thrombocytopenia)
• BLFS +10.2% (announces that Kolon Life Science, TissueGene’s exclusive licensee for Asia, including Korea, has received marketing approval for Invossa-K Inj for degenerative arthritis from the Korea Ministry of Food and Drug Safety)
• HPJ +8.7% (enters smart vacuum market with two new partnerships ),
• GMO +3.7% (FDA has granted Fast Track designation to SB-318 and SB-913, the Co’s clinical stage in vivo genome editing product candidates for the treatment of Mucopolysaccharidosis Type I and MPS II)
• ALDR +2.9% (favorable commentary on Thursday’s Mad Money),
• MYL +1.9% (Oncologic Drugs Advisory Committee votes unanimously to recommend MYL-1401O — proposed biosimilar to Genentech’s RHHBY unit HERCEPTIN)
• AZN +1.4% (following late sell-off on potential CEO departure announcement)
• MRSN +1.4% (Pfizer discloses 9.8% passive stake)
• GNW +1.2% (Genworth Financial and Oceanwide provide CFIUS update; timing of regulatory reviews will likely delay the completion of the transaction to later than the originally targeted time frame )
• MNK +0.9% (Phase 3 terlipressin trial achieves its enrollment target ahead of schedule – marks halfway point toward interim analysis of trial data), . 

Комментарии аналитиков:

• NTNX +9% (added to its Conviction Buy list at Goldman)
• AFMD +4.2% (initiated with Buy at Suntrust)
• ULTA +2.3% (upgraded and added to Conviction Buy List at Goldman)
• EXEL +1.9% (initiated with Buy at Suntrust)
• WMT +1.6% (upgraded and added to Conviction Buy List at Goldman)
• ROST +1.1% (upgraded to Outperform at Telsey Advisory Group)
• BA +0.8% (upgraded to Overweight from Neutral at JP Morgan)